Aldosterone-induced osteopontin expression in vascular smooth muscle cells involves MR, ERK, and p38 MAPK

Endocrine

Volumn 42, Issue 3, 2012, Pages 676-683

  Fu, Guo Xiang ^a   Xu, Chan Chan ^a   Zhong, Yuan ^a   Zhu, Ding Liang ^a,b   Gao, Ping Jin ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

Author keywords

Aldosterone; Osteopontin; Signal transduction; Vascular remodeling; Vascular smooth muscle cells

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ALDOSTERONE; MINERALOCORTICOID RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEOPONTIN; SPIRONOLACTONE; ANTISENSE OLIGONUCLEOTIDE; LUCIFERASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; CAROTID ARTERY INJURY; CELL MIGRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; TIME; VASCULAR SMOOTH MUSCLE; ANIMAL; BIOSYNTHESIS; CELL CULTURE; CELL MOTION; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSFECTION; IMMUNOHISTOCHEMISTRY; METABOLISM; NEOINTIMA; PATHOLOGY; SPRAGUE DAWLEY RAT; THORACIC AORTA; WESTERN BLOTTING;

ALDOSTERONE; ANIMALS; AORTA, THORACIC; BLOTTING, WESTERN; CAROTID ARTERY INJURIES; CELL MOVEMENT; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; LUCIFERASES; MAP KINASE SIGNALING SYSTEM; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NEOINTIMA; OLIGONUCLEOTIDES, ANTISENSE; OSTEOPONTIN; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, MINERALOCORTICOID; TRANSFECTION;

EID: 84878246840     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-012-9675-2     Document Type: Article

References (39)

1. E.R. O'Brien, M.R. Garvin, D.K. Stewart, T. Hinohara, J.B. Simpson, S.M. Schwartz, C.M. Giachelli, Osteopontin is synthesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques. Arterioscler. Thromb. 14, 1648-1656 (1994)
2. L. Liaw, M. Almeida, C.E. Hart, S.M. Schwartz, C.M. Giachelli, Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. Circ. Res. 74, 214-224 (1994)
3. K. Isoda, K. Nishikawa, Y. Kamezawa, M. Yoshida, M. Kusuhara, M. Moroi, N. Tada, F. Ohsuzu, Osteopontin plays and important role in the development of medial thickening and neointimal formation. Circ. Res. 91, 77-82 (2002)
4. T. Cascella, Y. Radhakrishnan, L.A. Maile, W.H. Busby Jr., K. Gollahon, A. Colao, D.R. Clemmons, Aldosterone enhances IGF-I-mediated signaling and biological function in vascular smooth muscle cells. Endocrinology 151, 5851-5864 (2010)
5. M. Han, J.K. Wen, B. Zheng, Z. Liu, Y. Chen, Blockade of integrin β3-FAK signaling pathway activated by osteopontin inhibits neointimal formation after balloon injury. Cardiovasc. Pathol. 16, 283-290 (2007)
6. M. Kurata, T. Okura, S. Watanabe, T. Fukuoka, J. Higaki, Osteopontin and carotid atherosclerosis in patients with essential hypertension. Clin. Sci. (Lond.) 111, 319-324 (2006)
7. C.M. Giachelli, N. Bae, M. Almeida, D.T. Denhardt, C.E. Alpers, S.M. Schwartz, Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J. Clin. Invest. 92, 1686-1696 (1993)
8. R. Rocha, A.E. Rudolph, G.E. Frierdich, D.A. Nachowiak, B.K. Kekec, E.A. Blomme, E.G. McMahon, J.A. Delyani, Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am. J. Physiol. Heart Circ. Physiol. 283, H1802-H1810 (2002)
9. D. Nagata, M. Takahashi, K. Sawai, T. Tagami, T. Usui, A. Shimatsu, Y. Hirata, M. Naruse, Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO syntheses activity. Hypertension 48, 165-171 (2006)
10. N. Sukor, Primary aldosteronism: from bench to bedside. Endocrine 41, 31-39 (2012)
11. R. Rocha, J.W. Funder, The pathophysiology of aldosterone in the cardiovascular system. Ann. N.Y. Acad. Sci. 970, 89-100 (2002)
12. S. Del Ry, D. Giannessi, M. Maltinti, M. Cabiati, C. Prontera, A. Iervasi, C. Caselli, A.M. Mazzone, D. Neglia, Increased plasma levels of osteopontin are associated with activation of the renin-aldosterone system and with myocardial and coronary micro-vascular damage in dilated cardiomyopathy. Cytokine 49, 325-330 (2010)
13. A. Kiyosue, D. Nagata, M. Myojo, T. Sato, M. Takahashi, H. Satonaka, R. Nagai, Y. Hirata, Aldosterone-induced osteopontin gene transcription in vascular smooth muscle cells involves glucocorticoid response element. Hypertens. Res. 34, 1283-1287 (2011)
14. T. Ishida, M. Ishida, J. Suero, M. Takahashi, B.C. Berk, Agonist-stimulated cytoskeletal reorganization and signal transduction at focal adhesions in vascular smooth muscle cells require c-Src. J. Clin. Invest. 103, 789-797 (1999)
15. X. Jin, X. Song, L. Li, Z. Wang, Y. Tao, L. Deng, M. Tang, W. Yi, Y. Cao, Blockade of AP-1 activity by dominant-negative TAM67 can abrogate the oncogenic phenotype in latent membrane protein 1-positive human nasopharyngeal carcinoma. Mol. Carcinog. 46, 901-911 (2007)
16. X. Jin, X. Ge, D.L. Zhu, C. Yan, Y.F. Chu, W.D. Chen, J. Liu, P.J. Gao, Expression and function of vascular endothelial growth factor receptors (Flt-1 and Flk-1) in vascular adventitial fibroblasts. J. Mol. Cell. Cardiol. 3, 292-300 (2007)
17. M. Usui, K. Egashira, K. Ohtani, C. Kataoka, M. Ishibashi, K. Hiasa, M. Katoh, Q. Zhao, S. Kitamoto, A. Takeshita, Anti-monocyte chemoattractant protein-1 gene therapy inhibits restenotic changes (neointimal hyperplasia) after balloon injury in rats and monkeys. FASEB J. 16, 1838-1840 (2002)
18. B. Pitt, F. Zannad, W.J. Remme, R. Cody, A. Castaigne, A. Perez, J. Palensky, J. Wittes, The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N. Engl. J. Med. 341, 709-717 (1999)
19. B. Pitt, G. Bakris, L.M. Ruilope, L. DiCarlo, R. Mukherjee, Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 118, 1643-1650 (2008)
20. L. Pascual-Le Tallec, M. Lombes, The mineralocorticoid receptor: a journey exploring its diversity and specificity of action. Mol. Endocrinol. 19, 2211-2221 (2005)
21. P.J. Fuller, M.J. Young, Mechanisms of mineralocorticoid action. Hypertension 46, 1227-1235 (2005)
22. C. Grossmann, M. Gekle, Nongenotropic aldosterone effects and the EGFR: interaction and biological relevance. Steroids 73, 973-978 (2008)
23. C. Grossmann, A.W. Krug, R. Freudinger, S. Mildenberger, K. Voelker, M. Gekle, Aldosterone-induced EGFR expression: interaction between the human mineralocorticoid receptor and the human EGFR promoter. Am. J. Physiol. Endocrinol. Metab. 292, E1790-E1800 (2007)
24. J. Irita, T. Okura, M. Kurata, K. Miyoshi, T. Fukuoka, J. Higaki, Osteopontin in rat renal fibroblasts: functional properties and transcriptional regulation by aldosterone. Hypertension 51, 507-513 (2008)
25. S. Sakurabayashi-Kitade, Y. Aoka, H. Nagashima, H. Kasanuki, N. Hagiwara, M. Kawana, Aldosterone blockade by spironolactone improves the hypertensive vascular hypertrophy and remodeling in angiotensin II overproducing transgenic mice. Atherosclerosis 206, 54-60 (2009)
26. F. Sam, Z. Xie, H. Ooi, D.L. Kerstetter, W.S. Colucci, M. Singh, K. Singh, Mice lacking osteopontin exhibit increased left ventricular dilation and reduced fibrosis after aldosterone infusion. Am. J. Hypertens. 17, 188-193 (2004)
27. J. Irita, T. Okura, S. Manabe, M. Kurata, K. Miyoshi, S. Watanabe, T. Fukuoka, J. Higaki, Plasma osteopontin levels are higher in patients with primary aldosteronism than in patients with essential hypertension. Am. J. Hypertens. 19, 293-297 (2006)
28. H. Otani, F. Otsuka, K. Inagaki, M. Takeda, T. Miyoshi, J. Suzuki, T. Mukai, T. Ogura, H. Makino, Antagonistic effects of bone morphogenetic protein-4 and -7 on renal mesangial cell proliferation induced by aldosterone through MAPK activation. Am. J. Physiol. Renal Physiol. 292, F1513-F1525 (2007)
29. C. Walczak, F. Gaignier, A. Gilet, F. Zou, S.N. Thornton, A. Ropars, Aldosterone increase VEGF-A production in human neutrophils through PI3K, ERK1/2 and p38 pathways. Biochim. Biophys. Acta 1813, 2125-2132 (2011)
30. Y. Zhan, S. Kim, Y. Izumi, Y. Izumiya, T. Nakao, H. Miyazaki, H. Iwao, Role of JNK, p38, and ERK in platelet-derived growth factor-induced vascular proliferation, migration and gene expression. Arterioscler. Thromb. Vasc. Biol. 23, 795-801 (2003)
31. Z.H. Zhang, Y. Yu, S.G. Wei, R.B. Felder, Aldosterone-induced brain MAPK signaling and sympathetic excitation are angiotensin II type-1 receptor dependent. Am. J. Physiol. Heart Circ. Physiol. 302, H742-H751 (2012)
32. A. Nguyen Dinh Cat, A.M. Briones, G.E. Callera, A. Yogi, Y. He, A.C. Montezano, R.M. Touyz, Adipocyte-derived factors regulate vascular smooth muscle cells through mineralocorticoid and glucocorticoid receptors. Hypertension 58, 479-488 (2011)
33. K. Isoda, Y. Kamezawa, M. Ayaori, M. Kusuhara, N. Tada, F. Ohsuzu, Osteopontin transgenic mice fed a high-cholesterol diet develop early fatty-streak lesions. Circulation 107, 679-681 (2003)
34. Y. Matsui, S.R. Rittling, H. Okamoto, M. Inobe, N. Jia, T. Shimizu, M. Akino, T. Sugawara, J. Morimoto, C. Kimura, S. Kon, D. Denhardt, A. Kitabatake, T. Uede, Osteopontin deficiency attenuates atherosclerosis in female apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 23, 1029-1034 (2003)
35. D. Panda, G.C. Kundu, B.I. Lee, A. Peri, D. Fohl, I. Chackalaparampil, B.B. Mukherjee, X.D. Li, D.C. Mukherjee, S. Seides, J. Rosenberg, K. Stark, A.B. Mukherjee, Potential roles of osteopontin and alphaVbeta3 integrin in the development of coronary artery restenosis after angioplasty. Proc. Natl. Acad. Sci. U.S.A. 94, 9308-9313 (1997)
36. J. Irita, T. Okura, M. Jotoku, T. Nagao, D. Enomoto, M. Kurata, V.R. Desilv, K. Miyoshi, Y. Matsui, T. Uede, D.T. Denhardt, S.R. Rittiling, J. Higaki, Osteopontin deficiency protects against aldosterone-induced inflammation, oxidative stress, and interstitial fibrosis in the kidney. Am. J. Physiol. Renal Physiol. 301, F833-F844 (2011)
37. S.M. Martin, J.L. Schwartz, C.M. Giachelli, B.D. Ratner, Enhancing the biological activity of immobilized osteopontin using a type-1 collagen affinity coating. J. Biomed. Mater. Res. A 70, 10-19 (2004)
38. H.E. Yim, K.H. Yoo, I.S. Bae, G.Y. Jang, Y.S. Hong, J.W. Lee, Aldosterone regulates cellular turnover and mitogen-activated protein kinase family expression in the neonatal rat kidney. J. Cell. Physiol. 219, 724-733 (2009)
39. Y. Nagai, K. Miyata, G.P. Sun, M. Rahman, S. Kimura, A. Miyatake, H. Kiyomoto, M. Kohno, Y. Abe, M. Yoshizumi, A. Nishiyama, Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1/2 in rat renal fibroblasts. Hypertension 46, 1039-1045 (2005)